Loading…
Supernus Pharmaceuticals, Inc. is projected to rise to $58.10 by 2027, a +25% move from its current price of $46.64. SUPN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $45.85 | $46.68 | $47.52 | +0.08% |
| May 30 | $45.54 | $46.71 | $47.91 | +0.16% |
| May 31 | $45.32 | $46.75 | $48.23 | +0.24% |
| Jun 1 | $45.14 | $46.79 | $48.50 | +0.31% |
| Jun 2 | $44.98 | $46.82 | $48.74 | +0.39% |
| Jun 3 | $44.84 | $46.86 | $48.97 | +0.47% |
| Jun 4 | $44.72 | $46.90 | $49.18 | +0.55% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $44.72 | $46.90 | $49.18 | +0.55% |
| Week 2 | $44.09 | $47.15 | $50.43 | +1.10% |
| Week 3 | $43.67 | $47.41 | $51.48 | +1.66% |
| Week 4 | $43.35 | $47.67 | $52.43 | +2.22% |
| Week 5 | $43.10 | $47.94 | $53.31 | +2.78% |
| Week 6 | $42.90 | $48.20 | $54.15 | +3.34% |
| Week 7 | $42.74 | $48.46 | $54.95 | +3.91% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Supernus Pharmaceuticals, Inc. is a biopharmaceutical company that engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its portfolio includes Qelbree for ADHD, GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease, Oxtellar XR for partial onset epilepsy seizures, APOKYN for acute and intermittent treatment of hypomobility or off episodes in advanced PD, Trokendi XR for epilepsy and migraine prophylaxis, XADAGO for off episodes in PD, and MYOBLOC for cervical dystonia and chronic sialorrhea.
The company also develops ONAPGO for motor fluctuations in adults with advanced PD and SPN-817, SPN-820, and SPN-443 across various CNS indications. It markets through wholesalers, specialty pharmacies, and distributors and was incorporated in 2005, with its headquarters in Rockville, Maryland.
Supernus Pharmaceuticals, Inc. (SUPN) is trading with a current price of $48.21 and a market capitalization of $2.8B. The stock is ranked 1779 by market capitalization. The 50-day simple moving average is $49.91 and the 200-day simple moving average is $48.83, indicating the stock currently sits near its longer-term average.
The 30-day price range runs from $42.77 to $54.35, with a defined support at $47.62 and resistance at $52.28. The stock’s sentiment in the near term is NEUTRAL, and annualized volatility stands at 30%.
A major floor 8.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 12.1% above — a clean break opens room to run.
A major ceiling 20.8% above — clearing it would confirm fresh momentum.
Key SUPN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of SUPN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $48.14 | Sell | $47.84 | Sell |
| MA 10 | $48.86 | Sell | $48.50 | Sell |
| MA 20 | $49.30 | Sell | $49.10 | Sell |
| MA 50 | $49.79 | Sell | $49.77 | Sell |
| MA 100 | $50.49 | Sell | $49.61 | Sell |
| MA 200 | $48.89 | Sell | $47.43 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.52 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -138.29 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.29 | Sell |
| ROC (12) | -9.49 | Sell |
| Bollinger %B (20,2) | 0.07 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.09 | Sell |
| Awesome (5,34) | -1.50 | Sell |
| Ultimate (7,14,28) | 31.73 | Neutral |
| Momentum (10) | -3.89 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 47.57 | Sell |
| ADX (14) | 12.32 | Neutral |
| ATR (14) | 0.90 | Info |
The near-term technical picture shows the stock trading within a broad range, with RSI at 40, suggesting neither overbought nor oversold pressure. The price is hovering around the SMA50 of $49.91 and slightly above the SMA200 of $48.83, indicating a convergent short-term trend. Key levels to watch are support at $47.62 and resistance at $52.28, while the 30-day range spans from $42.77 to $54.35.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $46.64 | $46.64 | $65.70 | 0% | Neutral | |
| $47.47 | $58.10 | $74.45 | +25% | Bullish | |
| $52.03 | $64.85 | $85.26 | +39% | Bullish | |
| $56.10 | $70.99 | $95.27 | +52% | Bullish | |
| $59.37 | $76.12 | $103.97 | +63% | Bullish | |
| $68.89 | $89.40 | $124.01 | +92% | Bullish | |
| $80.03 | $105.01 | $147.71 | +125% | Bullish | |
| $90.55 | $120.06 | $171.05 | +157% | Bullish | |
| $96.73 | $129.53 | $186.72 | +178% | Bullish | |
| $94.93 | $128.31 | $187.01 | +175% | Bullish | |
| $152.84 | $215.43 | $328.94 | +362% | Bullish | |
| $255.24 | $385.77 | $631.22 | +727% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $46.64 | $46.64 | $54.75 | +0.00% |
| June 2026 | $41.84 | $48.81 | $58.05 | +4.66% |
| July 2026 | $42.69 | $50.09 | $60.13 | +2.62% |
| August 2026 | $42.79 | $50.43 | $60.98 | +0.67% |
| September 2026 | $43.95 | $51.98 | $63.23 | +3.09% |
| October 2026 | $45.30 | $53.77 | $65.76 | +3.43% |
| November 2026 | $45.01 | $53.59 | $65.85 | -0.33% |
| December 2026 | $44.59 | $53.23 | $65.70 | -0.67% |
Click any year to see its month-by-month SUPN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Supernus Pharmaceuticals, Inc.'s 2026 outlook centres on $46.64, within a $46.64 to $65.70 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, SUPN could reach as high as $74.45, with a base case around $58.10 and support toward $47.47 — roughly +25% from $46.64. Momentum favours further upside here.
Expect SUPN to range from $52.03 to $85.26 through 2028. The $64.85 average target implies a +39% move from current prices. That is up +12% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The SUPN price prediction for 2029 points to an average of $70.99 (low $56.10, high $95.27) — a potential gain of +52% on today's $46.64. Momentum favours further upside here.
In 2030, SUPN is projected to trade between $59.37 and $103.97, averaging $76.12 — a potential gain of +63% from today's $46.64. That is up +7% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Supernus Pharmaceuticals, Inc.'s 2031 outlook centres on $89.40, within a $68.89 to $124.01 range. That is up +17% on the projected 2030 average. That marks a +92% change versus current levels. Momentum favours further upside here.
By 2032, SUPN could reach as high as $147.71, with a base case around $105.01 and support toward $80.03 — roughly +125% from $46.64. Buyers look set to stay in control over this stretch.
Expect SUPN to range from $90.55 to $171.05 through 2033. The $120.06 average target implies a +157% move from current prices. That is up +14% on the projected 2032 average. Momentum favours further upside here.
The SUPN price prediction for 2034 points to an average of $129.53 (low $96.73, high $186.72) — a potential gain of +178% on today's $46.64. Buyers look set to stay in control over this stretch.
In 2035, SUPN is projected to trade between $94.93 and $187.01, averaging $128.31 — a potential gain of +175% from today's $46.64. That is -1% versus the projected 2034 average. Momentum favours further upside here.
Supernus Pharmaceuticals, Inc.'s 2040 outlook centres on $215.43, within a $152.84 to $328.94 range. That is up +68% on the projected 2035 average. That marks a +362% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, SUPN could reach as high as $631.22, with a base case around $385.77 and support toward $255.24 — roughly +727% from $46.64. Momentum favours further upside here.
Investing $1,000 in SUPN today (≈ 21.440823 SUPN) could be worth
$8,271.19
+$7,271.19 (+727%) by 2050 · US Dollar
Based on the average projected SUPN price of $385.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in SUPNwould be worth at today's price.
$1,000 invested in SUPN on May 27, 2025 (≈ 30.674848 SUPN) would be worth
$1,430.67
+$430.67 (+43.1%) today · 1.43× · US Dollar
Based on a SUPN entry price of $32.6 vs. today's $46.64.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $48.69 | $957.9 | -4.2% |
| 1 month ago | $49.46 | $942.98 | -5.7% |
| 3 months ago | $55.75 | $836.59 | -16.3% |
| 6 months ago | $45.59 | $1,023.03 | +2.3% |
| 1 year ago | $32.6 | $1,430.67 | +43.1% |
| All time (5.0y) ago | $29.56 | $1,577.81 | +57.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our SUPN forecast.
Our base-case forecast reaches $93.00 around 2032.
Implied market cap at $93.00: $5.4B
The multi-year forecast paints a steadily rising path with bullish sentiment from 2027 onward. The 2030 average is $79.38 with a maximum of $108.45 and a minimum of $61.90, yielding an estimated ROI of 64.7% and a bullish outlook. The 2040 forecast shows an average of $225.36 and a max of $344.14, with a strong 367.4% ROI and bullish sentiment; by 2050, the average is projected at $405.56 with a max of $663.66, delivering a 741.2% ROI and bullish sentiment.
These figures illustrate a long-run upside potential, though these are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $79.38; min $61.90; max $108.45; ROI 64.7%; sentiment BULLISH.
Forecasts show a bullish trend from 2027 onward with rising averages (2027 avg $60.47, 2028 avg $67.09, 2029 avg $74.02, 2030 avg $79.38). 2026 is NEUTRAL with avg $48.21 and ROI 0%. These are estimates, not guarantees.
Yes. The 2040 forecast shows an average of $225.36 with a max of $344.14 and ROI 367.4%.
Current price is $48.21 and market cap is $2.8B.
The 30-day range is between $42.77 and $54.35.
Supernus Pharmaceuticals, Inc. Community Discussion
0Share your Supernus Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.